Related Experiment Video
Updated: Feb 3, 2026
Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies
Published on: October 7, 2021
[The dawn of neuroprotective therapy for glaucomatous optic neuropathy]
1Department of Ophthalmology, Gifu University School of Medicine, 40 Tsukasa-machi, Gifu 500-8705, Japan.
Background:
Neuroprotective therapy for glaucoma can be defined as treatment of the recalcitrant disease via direct modification of the molecular mechanism involving retinal ganglion cell death. I and my collaborators, at the dawn of the neuroprotective era, elaborated and conducted the following investigations in order to pursue our final goal, i.e., substantial improvement of the quality of life of glaucoma patients.
Methods And Results:
1. Investigation of in traocular pressure (IOP) independent prognostic factors in glaucomatous optic neuropathy. Clinical investigation along with multivariate analyses revealed that some IOP-independent factors including optic disc hemorrhage and compromised retrobulbar hemodynamics are associated with the development and progression of glaucomatous optic neuropathy. 2. Glaucoma therapy other than ocular hypotensive therapy. A long-term follow-up study demonstrated that calcium-channel blockers are efficacious in stabilizing the visual field in normal-tension glaucoma. 3. Establishment of animal models for glaucomatous optic neuropathy. Experimental animal models were created to conduct neuroprotective research for glaucomatous optic neuropathy: an IOP elevation model and an optic nerve crush model in the rat. In addition, a system was constructed for electrophysiological study in the rat to quantitatively investigate neuroprotective effect on the retina and the optic nerve. 4. Neuroprotective effects of several agents on experimental optic neuropathies. Several agents were studied for their neuroprotective effects on optic neuropathies induced in the rat. Some apoptosis-modifying agents were found to possess neuroprotective effects against optic neuropathy.
Conclusions:
IOP-independent prognostic factors exist in glaucomatous optic neuropathy. Glaucomatous optic neuropathy can be stabilized by IOP-unrelated therapy like calcium-channel blockers, at least in a subset of the disease. Modification of the apoptosis mechanism can protect retinal ganglion cells from damage caused by optic neuropathy in the rat models. All of the present studies suggest that neuroprotective therapy will probably become the treatment of choice in the near future for glaucomatous optic neuropathy.
Insights
Neuroprotective therapies show promise for glaucoma, identifying factors beyond intraocular pressure and demonstrating the efficacy of calcium-channel blockers and apoptosis-modifying agents in preserving vision.
Area of Science:
- Ophthalmology
- Neuroscience
- Pharmacology
Context:
- Glaucoma, a leading cause of irreversible blindness, is characterized by retinal ganglion cell death.
- Current treatments primarily focus on lowering intraocular pressure (IOP), but neuroprotective strategies offer a complementary approach.
- The development of neuroprotective therapies aims to directly modify the molecular mechanisms underlying retinal ganglion cell death.
Purpose:
- To investigate IOP-independent prognostic factors in glaucomatous optic neuropathy.
- To explore glaucoma therapies beyond ocular hypotensive treatments.
- To establish and utilize animal models for evaluating neuroprotective agents against optic neuropathy.
Summary:
- Clinical studies identified optic disc hemorrhage and compromised retrobulbar hemodynamics as IOP-independent factors in glaucoma progression.
- A long-term study indicated calcium-channel blockers can stabilize visual fields in normal-tension glaucoma.
- Experimental models in rats demonstrated that apoptosis-modifying agents possess neuroprotective effects against optic neuropathy.
Impact:
- Neuroprotective therapy, targeting mechanisms like apoptosis, holds potential for stabilizing glaucomatous optic neuropathy.
- Identifying IOP-independent factors aids in predicting disease progression and guiding treatment strategies.
- These findings suggest a future where neuroprotection becomes a primary treatment modality for glaucoma, improving patient quality of life.
Related Concept Videos
00:59Gene Therapy
01:26Group Therapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:22Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
01:28Drug Therapy
Antianxiety Medications
01:25Cognitive Therapy